Quick Answer
Tonix Pharmaceuticals Holding Corp. reported R&D Expense of $44.49 million for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $44.49M | +11.3% |
| 2024 | $39.97M | -53.9% |
| 2023 | $86.66M | +5.8% |
| 2022 | $81.88M | +18.9% |
| 2021 | $68.84M | +90.4% |
| 2020 | $36.16M | +98.8% |
| 2019 | $18.19M | +3.6% |
| 2018 | $17.56M | +31.6% |
| 2017 | $13.34M | -53.2% |
| 2016 | $28.53M | -19.6% |
| 2015 | $35.50M | +90.7% |
| 2014 | $18.62M | +300.4% |
| 2013 | $4.65M | +80.0% |
| 2012 | $2.58M | +123.1% |
| 2011 | $1.16M | +98.2% |
| 2010 | $584.3K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.29M | +1.9% | -14.1% |
| June 30, 2025 | $10.82M | +11.6% | +45.5% |
| March 31, 2025 | $7.44M | -42.2% | -18.4% |
| September 30, 2024 | $9.11M | -56.7% | -6.0% |
| June 30, 2024 | $9.70M | -55.9% | -24.6% |
| March 31, 2024 | $12.86M | -51.5% | -38.9% |
| September 30, 2023 | $21.05M | -5.2% | -4.2% |
| June 30, 2023 | $21.98M | +32.6% | -17.1% |
- Tonix Pharmaceuticals Holding Corp. showed an increase of +11.3% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Tonix Pharmaceuticals Holding Corp.’s r&d expense has grown by 7513.6% (from $584.3 thousand to $44.49 million).
- The most recent figure is from Tonix Pharmaceuticals Holding Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: